Two newly identified proteins that appear to play a critical role in the development of aggressive triple-negative breast cancer (TNBC) could also lead to potential new treatments, according to scientists at Icahn School of Medicine at Mount Sinai, the University of Kentucky, MD Anderson Cancer Center, and several medical centers in China.
Allium vegetables comprise approximately 500 species, the most common including onions, leeks, garlic, chives, and shallots. They have been valued throughout history for their flavor as well as their medicinal properties. Rich in health-promoting flavanols and organosulfur compounds, alliums have increasingly attracted the interest of the medical community for their potential to play a part in preventing cancer.
According to the American Institute for Cancer Research, about one third of cancers in high-income countries can be attributed to preventable factors such as nutrition and physical activity. In the United States, breast cancer is the most commonly diagnosed cancer in women, astoundingly impacting one in every eight women in their lifetimes.
At this time, we don’t know exactly why many women develop breast cancer, but the following tips from the Dubin Breast Center’s Clinical Nutrition Coordinator Alexandra Rothwell, RD, can help to reduce your risk for cancer and may help to prevent recurrence among cancer survivors.
Hospital and community leaders, local legislators, and residents of Western Queens gathered on Monday, October 21, to break ground on a $125 million expansion project at Mount Sinai Queens, which will enhance emergency and outpatient care, and diagnostic and laboratory services, when it is completed in 2016.
Personalized Medicine is a rapidly evolving approach to patient care that incorporates an individual’s genetic information into a customized prevention or treatment plan. Mapping a person’s total genetic makeup or whole genome sequencing has created mountains of data about variations in our human genetic code. As this experience has grown, some of these variations have been linked to risks for certain diseases, or in some cases the likelihood that a person will respond to a particular treatment. Individuals may now submit a DNA sample and obtain their genetic sequence with accompanying risk association analysis for a few hundred dollars. Can this technology however be harnessed to drive better outcomes for patients diagnosed with cancer? Many clinicians and scientists argue that we are not there yet.